Fjarde AP Fonden Fourth Swedish National Pension Fund Grows Position in Abbott Laboratories $ABT

Fjarde AP Fonden Fourth Swedish National Pension Fund grew its position in Abbott Laboratories (NYSE:ABT) by 2.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 548,204 shares of the healthcare product maker’s stock after buying an additional 12,300 shares during the quarter. Abbott Laboratories accounts for approximately 0.6% of Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings, making the stock its 27th biggest holding. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Abbott Laboratories were worth $68,684,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Flagship Wealth Advisors LLC increased its position in shares of Abbott Laboratories by 208.6% in the fourth quarter. Flagship Wealth Advisors LLC now owns 2,160 shares of the healthcare product maker’s stock valued at $271,000 after buying an additional 1,460 shares in the last quarter. Petersen Hastings Wealth Advisors Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at $349,000. Parallel Advisors LLC increased its position in shares of Abbott Laboratories by 1.9% in the fourth quarter. Parallel Advisors LLC now owns 131,090 shares of the healthcare product maker’s stock valued at $16,424,000 after buying an additional 2,432 shares in the last quarter. TruNorth Capital Management LLC increased its position in shares of Abbott Laboratories by 36.0% in the fourth quarter. TruNorth Capital Management LLC now owns 4,337 shares of the healthcare product maker’s stock valued at $543,000 after buying an additional 1,148 shares in the last quarter. Finally, Straight Path Wealth Management increased its position in shares of Abbott Laboratories by 48.2% in the fourth quarter. Straight Path Wealth Management now owns 5,406 shares of the healthcare product maker’s stock valued at $677,000 after buying an additional 1,759 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of analyst reports. Leerink Partners decreased their price objective on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research note on Tuesday, April 21st. TD Cowen decreased their price objective on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Stifel Nicolaus decreased their price objective on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Piper Sandler decreased their price objective on Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Finally, Benchmark decreased their price objective on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $119.09.

Insider Activity

In other news, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel J. Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $91.20 on Friday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $139.06. The firm has a 50 day moving average price of $92.80 and a 200 day moving average price of $109.31. The company has a market cap of $158.85 billion, a price-to-earnings ratio of 25.55, a PEG ratio of 1.51 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the previous year, the firm earned $1.09 earnings per share. Abbott Laboratories’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.